menu
    • menu
    [{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"||NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"KYORIN PHARMACEUTICAL CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ KYORIN PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharma \/ KYORIN PHARMACEUTICAL CO LTD"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ RBC Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ RBC Capital Markets"}]

    Find Pulmonary/Respiratory Diseases Clinical Drug Pipeline Developments & Deals by aTyr Pharma

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            aTyr’s Efzofitimod Passes Fourth Positive DSMB Review in Phase 3

                            Details : ATYR1923 (efzofitimod) is a tRNA synthetase-derived therapy based on a naturally occurring, lung-enriched, splice variant of HARS. It is being evaluated for pulmonary sarcoidosis.

                            Product Name : ATYR1923

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 06, 2025

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Ph 3 EFZO-FIT™ Study

                            Details : ATYR1923 (efzofitimod) is a tRNA synthetase-derived therapy based on a naturally occurring, lung-enriched, splice variant of HARS. It is being evaluated for pulmonary sarcoidosis.

                            Product Name : ATYR1923

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 10, 2024

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            aTyr Pharma Completes Phase 3 Enrollment for EFZO-FIT™ Study in Pulmonary Sarcoidosis

                            Details : ATYR1923 (efzofitimod) is a tRNA synthetase-derived therapy based on a naturally occurring, lung-enriched, splice variant of HARS. It is being evaluated for pulmonary sarcoidosis.

                            Product Name : ATYR1923

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 22, 2024

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            aTyr Reports Second Positive DSMB Review For Efzofitimod In Sarcoidosis Trial

                            Details : ATYR1923 (efzofitimod) is a tRNA synthetase-derived therapy based on a naturally occurring, lung-enriched, splice variant of HARS. It is being evaluated for pulmonary sarcoidosis.

                            Product Name : ATYR1923

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 14, 2024

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            aTyr Announces Expanded Access Program for EFZO-FIT™ Trial Participants

                            Details : ATYR1923 (efzofitimod), a tRNA synthetase-derived therapy, is being evaluated for pulmonary sarcoidosis, targeting a lung-enriched splice variant of HARS.

                            Product Name : ATYR1923

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 21, 2024

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT Study of Efzofitimod in Patients with SS...

                            Details : Efzofitimod is a first-in-class biologic immunomodulator, under phase 2 clinical trials for systemic sclerosis-related interstitial lung disease. It selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve inflammation without...

                            Product Name : ATYR1923

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 31, 2023

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : RBC Capital Markets

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            aTyr Pharma Announces Pricing of Public Offering of Common Stock

                            Details : aTyr intends to use the net proceeds for general corporate purposes, including the ongoing development of ATYR1923 (efzofitimod) and the expansion of its clinical development program to include a planned Phase 2 study of efzofitimod in patients with syst...

                            Product Name : ATYR1923

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            September 02, 2023

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : RBC Capital Markets

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 202...

                            Details : ATYR1923 (efzofitimod) is a potential first-in-class, works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent ...

                            Product Name : ATYR1923

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 31, 2023

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efzofitimod,Pirfenidone

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

                            Details : ATYR1923 (efzofitimod) is a potential first-in-class, works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent ...

                            Product Name : ATYR1923

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 19, 2023

                            Lead Product(s) : Efzofitimod,Pirfenidone

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            aTyr Pharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosi...

                            Details : ATYR1923 (efzofitimod), a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the FC region of a human antibody, is a selective modulator of neuropilin-2 that downregulates innate and adaptive immune response in i...

                            Product Name : ATYR1923

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 18, 2023

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth